253 related articles for article (PubMed ID: 11845988)
1. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
Studzian K; Wasowska M; Piestrzeniewicz MK; Wilmańska D; Szmigiero L; Oszczapowicz I; Gniazdowski M
Neoplasma; 2001; 48(5):412-8. PubMed ID: 11845988
[TBL] [Abstract][Full Text] [Related]
2. Sequence specificity of formaldehyde-mediated covalent binding of anthracycline derivatives to DNA.
Szulawska A; Gniazdowski M; Czyz M
Biochem Pharmacol; 2005 Jan; 69(1):7-18. PubMed ID: 15588709
[TBL] [Abstract][Full Text] [Related]
3. Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives.
Di Marco A; Casazza AM; Gambetta R; Supino R; Zunino F
Cancer Res; 1976 Jun; 36(6):1962-6. PubMed ID: 773533
[TBL] [Abstract][Full Text] [Related]
4. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety.
Ciesielska E; Studzian K; Wasowska M; Oszczapowicz I; Szmigiero L
Cell Biol Toxicol; 2005; 21(3-4):139-47. PubMed ID: 16328893
[TBL] [Abstract][Full Text] [Related]
6. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.
Supino R; Necco A; Dasdia T; Casazza AM; Di Marco A
Cancer Res; 1977 Dec; 37(12):4523-8. PubMed ID: 922737
[TBL] [Abstract][Full Text] [Related]
7. Antileukemic activity of synthetic daunomycinone derivatives bearing modifications in the glycosidic moiety.
Perchellet EM; Sperfslage BJ; McIlvain CJ; Aligiannis N; Pouli N; Marakos P; Skaltsounis AL; Perchellet JP
Anticancer Res; 2001; 21(6A):3957-67. PubMed ID: 11911277
[TBL] [Abstract][Full Text] [Related]
8. [14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin].
Povarov LS; Leont'eva OV; Bernaki PD; Olsuf'eva EN; Salimova EI; Pera P; Preobrazhenskaia MN
Bioorg Khim; 1995 Dec; 21(12):925-32. PubMed ID: 8602889
[TBL] [Abstract][Full Text] [Related]
9. Quantitative models for growth inhibition of human leukemia cells by antitumor anthracycline derivatives.
Kanter PM; Schwartz HS
Cancer Res; 1979 Sep; 39(9):3661-72. PubMed ID: 476691
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of new N-substituted daunorubicin derivatives.
Mazerska Z; Woynarowska B; Stefanska B; Borowski E; Martelli S
Drugs Exp Clin Res; 1987; 13(6):345-51. PubMed ID: 3308387
[TBL] [Abstract][Full Text] [Related]
11. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA.
Li LH; Swenson DH; Schpok SL; Kuentzel SL; Dayton BD; Krueger WC
Cancer Res; 1982 Mar; 42(3):999-1004. PubMed ID: 6174220
[TBL] [Abstract][Full Text] [Related]
12. Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation.
Czyz M; Szulawska A; Bednarek AK; Düchler M
Biochem Pharmacol; 2005 Nov; 70(10):1431-42. PubMed ID: 16185667
[TBL] [Abstract][Full Text] [Related]
13. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
Taatjes DJ; Gaudiano G; Resing K; Koch TH
J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
[TBL] [Abstract][Full Text] [Related]
14. Physical and biological characteristics of the antitumor drug actinomycin D analogues derivatized at N-methyl-L-valine residues.
Takusagawa F; Wen L; Chu W; Li Q; Takusagawa KT; Carlson RG; Weaver RF
Biochemistry; 1996 Oct; 35(40):13240-9. PubMed ID: 8855963
[TBL] [Abstract][Full Text] [Related]
15. Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron.
Taatjes DJ; Gaudiano G; Koch TH
Chem Res Toxicol; 1997 Sep; 10(9):953-61. PubMed ID: 9305576
[TBL] [Abstract][Full Text] [Related]
16. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
17. Biological properties of new derivatives of daunorubicin.
Wasowska-Lukawska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
In Vivo; 2007; 21(2):413-6. PubMed ID: 17436596
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
[TBL] [Abstract][Full Text] [Related]
19. Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
Fenick DJ; Taatjes DJ; Koch TH
J Med Chem; 1997 Aug; 40(16):2452-61. PubMed ID: 9258351
[TBL] [Abstract][Full Text] [Related]
20. Oxazolinodoxorubicin - a promising new anthracycline.
Lukawska M; Klopotowska D; Milczarek M; Wietrzyk J; Studzian K; Szmigiero L; Porebska A; Oszczapowicz I
Anticancer Res; 2012 Jul; 32(7):2959-65. PubMed ID: 22753760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
